HealthNewsAPI
Trump signs order fast tracking review of psychedelics for mental health disorders - NPR
Overview
President Trump signed an executive order directing federal agencies to fast-track review of certain psychedelic drugs, including psilocybin and ibogaine, for treating mental health conditions and allocated $50 million to support the effort. New clinical evidence that a ketamine infusion followed by low-dose buprenorphine can rapidly and durably reduce suicidal ideation adds clinical momentum to the administration’s rationale for accelerating research on fast-acting psychiatric drugs and could broaden the scope of prioritized compounds and trials.
Entities
ORGNPRORGWhite HouseORGFederal Government
Relationship Graph
Click a connection line between nodes to view confidence and evidence.
Nodes: 9 · Connections: 8
Caused by
Led to
Related to
Same event
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Click a connection for evidence · click a node to open it
Select a connection to see why these events are linked.